



Coronavirus Disease 2019 (COVID-19)

MENU >

Commercial Laboratory Seroprevalence Survey Data

Updated Sept. 18, 2020

[Print](#)

About this survey

CDC is partnering with commercial laboratories to conduct and publish results from a large-scale geographic seroprevalence survey that has tested de-identified clinical blood specimens from people in Connecticut, Louisiana, Minnesota, Missouri, the New York City metro area (Manhattan, Bronx, Queens, Kings, and Nassau), the Philadelphia metro area (Bucks, Chester, Cumberland, Delaware, Lancaster, Montgomery, Philadelphia), the San Francisco Bay Area (Marin, Contra Costa, Alameda, Santa Clara, San Mateo, and San Francisco), South Florida (Miami-Dade, Broward, Palm Beach, and Martin), Utah, and the Western Washington Region (King, Snohomish, Pierce, Kitsap, and Grays Harbor) for antibodies for the virus that causes COVID-19.

The survey includes people who had blood specimens tested for reasons unrelated to COVID-19, such as for a routine or sick visit during which blood was collected and tested by commercial laboratories in participating areas from each of the 10 sites. CDC aims to test about 1,800 samples collected from each of these 10 areas, approximately every 3–4 weeks. The results of these subsequent analyses are available on our [interactive website](#) and will be updated as samples continue to be analyzed. Researchers are looking to see what percentage of people tested already have antibodies against SARS-CoV-2, and how that percentage changes over time in each area.

More on the methodology used in this study is available online, [Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020](#) [↗](#).

Learn about the limitations of this survey and [how to interpret these serology results](#).

Results from ten sites


CDC has received results from people in Connecticut, Louisiana, Minnesota, Missouri, the New York City metro area (Manhattan, Bronx, Queens, Kings, and Nassau), the Philadelphia metro area (Bucks, Chester, Cumberland, Delaware, Lancaster, Montgomery, Philadelphia), the San Francisco Bay Area (Marin, Contra Costa, Alameda, Santa Clara, San Mateo, and San Francisco), South Florida (Miami-Dade, Broward, Palm Beach, and Martin), Utah, and the Western Washington Region (King, Snohomish, Pierce, Kitsap, and Grays Harbor) from blood samples collected by commercial laboratories as part of routine patient care.

The numbers listed below are rounded. The unrounded estimates are available online, [Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020](#) [↗](#).

The bottom chart shows the seroprevalence estimates for all sites and rounds. <https://www.cdc.gov/cases-updates/commercial-lab-surveys.html#interpreting-serology-results>
Use the information tooltips for more details on the data elements shown.

Site the study

- CT
- LA
- MN
- MO
- NYC
- PHL
- S. FL
- SF
- UT
- W. WA



[Go to Tableau Public](#)

Interactive Dashboard

View our interactive dashboard highlighting detailed data for each of the 10 sites surveyed in this study.

Last Updated Sept. 18, 2020

Content source: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases